|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.00 - 0.00|
|52 Week Range|
|PE Ratio (TTM)||41.39|
|Dividend & Yield||0.78 (2.90%)|
|1y Target Est||N/A|
The Samsung conglomerate is furthering its efforts to build a full-fledged prescription-drugs business, signing its first deal to develop novel drugs for hard-to-treat diseases.
South Korea's Samsung group announced it would start producing original prescription drugs, heralding its shift into a risky but potentially lucrative business area. The sprawling conglomerate's biopharmaceutical ...
In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis.